Trofinetide—a new chapter in rett syndrome’s treatment

Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies. Although further research is needed to assess potential adverse even...

Descripción completa

Detalles Bibliográficos
Autor principal: Furqan, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687465/
https://www.ncbi.nlm.nih.gov/pubmed/38035006
http://dx.doi.org/10.3389/fphar.2023.1284035
_version_ 1785151984975740928
author Furqan, Muhammad
author_facet Furqan, Muhammad
author_sort Furqan, Muhammad
collection PubMed
description Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies. Although further research is needed to assess potential adverse events, Trofinetide’s notable efficacy signifies a significant advancement in Rett syndrome treatment, offering a new therapeutic avenue with the potential to ameliorate the condition.
format Online
Article
Text
id pubmed-10687465
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106874652023-11-30 Trofinetide—a new chapter in rett syndrome’s treatment Furqan, Muhammad Front Pharmacol Pharmacology Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies. Although further research is needed to assess potential adverse events, Trofinetide’s notable efficacy signifies a significant advancement in Rett syndrome treatment, offering a new therapeutic avenue with the potential to ameliorate the condition. Frontiers Media S.A. 2023-11-16 /pmc/articles/PMC10687465/ /pubmed/38035006 http://dx.doi.org/10.3389/fphar.2023.1284035 Text en Copyright © 2023 Furqan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Furqan, Muhammad
Trofinetide—a new chapter in rett syndrome’s treatment
title Trofinetide—a new chapter in rett syndrome’s treatment
title_full Trofinetide—a new chapter in rett syndrome’s treatment
title_fullStr Trofinetide—a new chapter in rett syndrome’s treatment
title_full_unstemmed Trofinetide—a new chapter in rett syndrome’s treatment
title_short Trofinetide—a new chapter in rett syndrome’s treatment
title_sort trofinetide—a new chapter in rett syndrome’s treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687465/
https://www.ncbi.nlm.nih.gov/pubmed/38035006
http://dx.doi.org/10.3389/fphar.2023.1284035
work_keys_str_mv AT furqanmuhammad trofinetideanewchapterinrettsyndromestreatment

Ejemplares similares